HomeCompareIZQVF vs MAIN

IZQVF vs MAIN: Dividend Comparison 2026

IZQVF yields 9.54% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.91M in total portfolio value
10 years
IZQVF
IZQVF
● Live price
9.54%
Share price
$20.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.6K
Annual income
$1,738.36
Full IZQVF calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — IZQVF vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIZQVFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IZQVF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IZQVF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IZQVF
Annual income on $10K today (after 15% tax)
$810.68/yr
After 10yr DRIP, annual income (after tax)
$1,477.61/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,175,916.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IZQVF + MAIN for your $10,000?

IZQVF: 50%MAIN: 50%
100% MAIN50/50100% IZQVF
Portfolio after 10yr
$23.99M
Annual income
$20,105,218.74/yr
Blended yield
83.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

IZQVF
No analyst data
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IZQVF buys
0
MAIN buys
0
No recent congressional trades found for IZQVF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIZQVFMAIN
Forward yield9.54%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$37.6K$47.95M
Annual income after 10y$1,738.36$40,208,699.11
Total dividends collected$13.5K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: IZQVF vs MAIN ($10,000, DRIP)

YearIZQVF PortfolioIZQVF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,654$953.74$12,464$1,223.78$810.00MAIN
2$13,508$1,038.76$16,353$2,343.58$2.8KMAIN
3$15,579$1,125.29$23,105$4,724.42$7.5KMAIN
4$17,883$1,212.90$36,226$10,256.23$18.3KMAIN
5$20,435$1,301.15$65,426$24,707.64$45.0KMAIN
6$23,256$1,389.63$142,101$68,562.02$118.8KMAIN
7$26,361$1,477.94$388,521$228,799.95$362.2KMAIN
8$29,772$1,565.72$1,397,868$961,169.80$1.37MMAIN
9$33,509$1,652.63$6,884,663$5,313,459.69$6.85MMAIN
10$37,593$1,738.36$47,947,060$40,208,699.11$47.91MMAIN

IZQVF vs MAIN: Complete Analysis 2026

IZQVFStock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Full IZQVF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this IZQVF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IZQVF vs SCHDIZQVF vs JEPIIZQVF vs OIZQVF vs KOIZQVF vs ARCCIZQVF vs HTGCIZQVF vs GBDCIZQVF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.